A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

enlightenVue Reports Single-Use Micro Endoscope Receives FDA 510(k) Clearance

What To Know

  • “It has only taken two and a half years from the initial sketch to 510(k) clearance, and this incredible technology is now poised to disrupt the market and offer a new level of safety and protection to patients.
  • The novel micro-endoscope allows for a combination of diagnostic and interventional procedures, simplifies the patient’s overall experience from diagnosis to treatment, and gives the provider a wide range of clinical options.

enlightenVue creators of the surgiVue™ single-use platform of micro endoscopes announced today that their product has received 510(k) marketing clearance from the Federal Drug Administration (FDA).

According to the FDA: “The use of the enlightenVue Microendoscopy System is intended for the visualization of body cavities, hollow organs, and canals. It is also designed to be introduced through natural body orifices cavities or surgical incisions through introducers, trocars, needles, sheaths, or other devices with lumens having inside diameters larger than the outer diameter of the endoscope.”

Receiving this broad and general indication from the FDA gives enlightenVue the ability to market the unique surgiVue endoscope for multiple clinical and surgical procedures. EnlightenVue will immediately pursue several clinical trials in numerous medical and surgical specialties.

“This is the only two millimeter, single-use microendoscope on the market with two working channels,” said Giacomo Basadonna, Chief Executive Officer. “The surgiVue endoscope will protect patients from the risk of hospital-acquired infections that can be contracted from reusable endoscopes, as indicated by several FDA guidance documents. Additionally, the presence of two working channels allows health care providers to perform interventional procedures (rather than simple diagnostic ones) in a minimally invasive setting.”

“We are proud to have enlightenVue as an Alira Health Ventures portfolio company and are impressed with the speed and efficiency with which they achieved FDA clearance,” said Gabriele Brambilla, Chief Executive Officer of Alira Health and head of the firm’s investment arm, Alira Health Ventures. “It has only taken two and a half years from the initial sketch to 510(k) clearance, and this incredible technology is now poised to disrupt the market and offer a new level of safety and protection to patients.”

EnlightenVue’s microendoscope is single-use and does not require cleaning and/or re-sterilization, eliminating the risk of patient-to-patient transmission of microorganisms caused by difficult to disinfect and sterilize reusable endoscopes. This is of importance during the current viral pandemic where direct contagion must be avoided. In addition, the single-use surgiVue endoscope provides financial advantages to the healthcare system by eliminating the sterilization, repair and personnel costs associated with reusable endoscopes, reducing downtime and inventory logistics. The novel micro-endoscope allows for a combination of diagnostic and interventional procedures, simplifies the patient’s overall experience from diagnosis to treatment, and gives the provider a wide range of clinical options.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy